Literature DB >> 30760414

Clear cell renal cell carcinoma bone metastasis: What should be considered in prognostic evaluation.

Zixiong Huang1, Yiqing Du1, Xiaopeng Zhang1, Huixin Liu2, Shijun Liu1, Tao Xu3.   

Abstract

INTRODUCTION: Knowledge of clear cell renal cell carcinoma bone metastasis (ccRCC-BM) remains scarce. This study depicts clinical, pathological and outcome features of the disease and provides suggestions to establish prognosis prediction system more appropriate for ccRCC-BM.
MATERIALS AND METHODS: Patients with ccRCC-BM had clinical, pathological data collected. Kaplan-Meier survival analysis was used for outcome profiles. Prognostic risks were evaluated using MSKCC/Motzer score. Univariate and multivariate logistic regression were performed to investigate association between clinical, pathological features and prognosis.
RESULTS: In the series containing 106 ccRCC-BM patients with 4:1 male predominance, 44.3% of them had synchronous bone metastasis and 28.3% had multi-organ metastasis. Axial bone was prone to bone metastasis and the incidence of severe skeletal-related events was 54.7%. Curative bone lesion resection was performed in 70.7% patients. The median overall survival (mOS) time was 45 months for all and 32 months for those in unfavorable risk stratification. Shorter time to bone metastasis (TTBM) [OR 1.019, 95% CI (1.007, 1.031)], elderly age [OR 1.040, 95% CI (1.001, 1.080)], concomitant multi-organ metastasis [OR 3.883, 95% CI (1.375, 10.967)] and carbonic anhydrase (CA)-IX expression loss [OR 58.824, 95% CI (2.653, 1000)] were associated with poor prognosis.
CONCLUSION: The outcome of ccRCC-BM remained poor in unfavorable risk stratification. Bone lesion resection accompanied by systematic therapy for selected patient could improve prognosis. Shorter TTBM, elderly age, concomitant multi-organ metastasis and the expression loss of CA-IX along with gender-bias, feasibility for surgical treatment are suggested to be incorporated in modified ccRCC-BM-specific prognosis prediction system.
Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Bone metastasis; Clear cell renal cell carcinoma; MSKCC/Motzer score; Outcomes; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 30760414     DOI: 10.1016/j.ejso.2019.01.221

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  [Clinical and pathological analysis of small renal cell carcinoma].

Authors:  X P Zhang; Z X Huang; L P Yu; X W Zhang; Q Li; S J Liu; T Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

2.  Survival nomogram for patients with bone metastatic renal cell carcinoma: A population-based study.

Authors:  Keyi Wang; Zonglin Wu; Guangchun Wang; Heng Shi; Jinbo Xie; Lei Yin; Tianyuan Xu; Weipu Mao; Bo Peng
Journal:  Int Braz J Urol       Date:  2021 Mar-Apr       Impact factor: 1.541

3.  Development and Validation of a Predictive Model to Evaluate the Risk of Bone Metastasis in Kidney Cancer.

Authors:  Shengtao Dong; Hua Yang; Zhi-Ri Tang; Yuqi Ke; Haosheng Wang; Wenle Li; Kang Tian
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

4.  Risk Factors, Prognostic Factors, and Nomograms for Bone Metastasis in Patients with Newly Diagnosed Clear Cell Renal Cell Carcinoma: A Large Population-Based Study.

Authors:  Hongmin Zhou; Sheng Yang; Tiancheng Xie; Longfei Wang; Sen Zhong; Tianyang Sheng; Guoxin Fan; Xiang Liao; Yunfei Xu
Journal:  Front Surg       Date:  2022-04-01

Review 5.  Role of metastasectomy in the management of renal cell carcinoma.

Authors:  Mark Mikhail; Kevin J Chua; Labeeqa Khizir; Alexandra Tabakin; Eric A Singer
Journal:  Front Surg       Date:  2022-07-29

Review 6.  Metatarsal metastasis from clear cell renal cell carcinoma: a case report and literature review.

Authors:  Hongzeng Wu; Ruoqi Han; Qianqian Zhang; Yi Zhao; Helin Feng
Journal:  BMC Urol       Date:  2020-02-24       Impact factor: 2.264

7.  Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis.

Authors:  Minyong Kang; Joongwon Choi; Jungyu Kim; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Soo Jeon; Hyun Moo Lee; Se Hoon Park; Cheryn Song; Seong Il Seo
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.